Approved novel therapies enter early commercialization and follow-up
Bepirovirsen is FDA-approved for chronic HBV, with about one in five eligible patients maintaining undetectable virus off antivirals for at least six months; Voceryq’s accelerated approval requires confirmatory work. Recent approvals include gefurulimab, obinutuzumab, Bixlenvo, a type 1 diabetes immunotherapy, and a novel accelerated-approval head and neck cancer treatment; durability, safety, eligible populations and uptake need follow-up.
Sources (5)
Updated Nov 17, 2026